2026-05-10 · 2026-05 / week-1

DXYZ Trades Like SpaceX Direct, but the ATM Is Still Open

DXYZ Trades Like SpaceX Direct, but the ATM Is Still Open

Summary: Destiny Tech100 (NYSE: DXYZ) was quoted at $54.60 in the latest market snapshot on Friday, May 8, 2026, 7:53 PM EDT, even though the fund's latest official net asset value was only $19.97 per share as of December 31, 2025. The same February 11, 2026 SEC supplement says the vehicle can still sell up to $1.0 billion of stock through Jefferies and had already sold 8,121,853 shares for $244.6 million of net proceeds in the fourth quarter of 2025. The market is paying a direct-private-asset price for a public wrapper that still has an open self-help valve.

Opportunity Ranking

Rank Idea Discovery Lane Why It May Be Best Now Evidence Freshness Catalyst Window Asymmetry Main Reason to Reject
1 Short DXYZ at 2.73x latest official NAV with a live $1.0 billion ATM U.S. public wrapper / private-tech closed-end fund The stock still trades like direct SpaceX and Anthropic access even though the last official NAV was $19.97, 46.3% of the year-end portfolio sat in a Treasury money market fund, and the issuer still has a live at-the-market sale agreement. OpenAI finance snapshot dated May 8, 2026; SEC supplement dated February 11, 2026 with December 31, 2025 NAV and February 6, 2026 deployment update. Unscheduled but observable ATM issuance, next official NAV / portfolio update, and any cooling in wrapper-premium demand. Premium compression can be large even without a collapse to NAV, while a large part of the bull case depends on sentiment outrunning issuer self-help. Borrow availability is uncertain and stale NAV can fuel squeeze narratives if private marks rise sharply.
2 ENN Energy mixed-consideration privatization spread Broader Asia / Hong Kong event-driven The proposal points to a stated value of HK$80.00 per ENN share while recent disclosure-of-dealing prices still printed around HK$65.30. ENN interim report dated March 28, 2026 and Rule 22 dealing disclosure dated April 14, 2026. Scheme process and regulatory approvals through 2026. Nominal spread is large. Mixed stock-and-cash consideration, PRC and Hong Kong process risk, and a multi-leg structure make it too complex for the cleanest daily note.
3 Long Treatt residual cash spread into the Dohler takeout Europe / U.K. cash acquisition Dohler's recommended offer is 305.0p per share while recent market coverage still showed Treatt around 299.5p. Investegate release dated April 29, 2026 and Stockopedia quote page surfaced May 10, 2026. Scheme timetable is real, but completion is expected in Q3 2026. Event path is straightforward. The spread is real but thin, and the surprise content is weaker than DXYZ's still-open premium valve.
4 Short Taiyo Holdings above the KKR tender price Japan TOB / above-bid special situation Taiyo was recently quoted around JPY 4,878 against KKR's JPY 4,750 tender price. Taiyo official tender announcement dated March 31, 2026; Fintel Japan quote page surfaced May 10, 2026. Tender period runs into October 2026. Above-bid trading can work on paper. Japanese bump risk and the long tender window make the timing worse and the pain path wider than DXYZ.

Selected opportunity: Short DXYZ at a still-extreme premium to the latest official NAV.

Why this one now: The disagreement is inside the structure, not just the story. DXYZ is not merely expensive. It is expensive while the fund still has a documented mechanism to issue fresh stock above NAV.

What should surprise the reader: A sophisticated reader should not be surprised that investors want SpaceX, Anthropic, OpenAI, or xAI exposure. The surprise is that they are still paying a direct-ownership multiple for a wrapper whose own SEC filing shows a large cash-like sleeve and a live $1.0 billion issuance program.

The Setup

Destiny Tech100 is a listed closed-end vehicle designed to own late-stage private technology exposure. That structure matters more than the brand names. This is not a direct SpaceX share, not a direct Anthropic share, and not a synthetic OpenAI stub. It is a fund.

The latest hard balance-sheet disclosure is the company's February 11, 2026 prospectus supplement. That filing put net asset value at $19.97 per share as of December 31, 2025. It also laid out a roughly $434.0 million portfolio, of which $205.3 million was still in cash and cash equivalents. The single biggest line item was not SpaceX. It was a Treasury money market fund at 46.3% of the portfolio.

The filing also showed why the market got excited. Direct economic exposure to SpaceX sat at 12.6% through DXYZ SpaceX I LLC and another 3.7% through MWAM VC SpaceX-II, LLC. OpenAI exposure sat at 2.1%. xAI sat at 3.5%. After year-end, the fund used existing cash and cash equivalents to add about $127.0 million of new exposure across Anthropic, Chaos Industries, and Hermeus by February 6, 2026.

That is the bullish narrative. The bearish fact is just as important. The same filing sits on top of an at-the-market sale program with Jefferies for up to $1.0 billion of common stock. This is not hypothetical. From October 1, 2025 through December 31, 2025, the fund sold 8,121,853 shares and raised roughly $244.6 million of net proceeds.

The trade is not that the underlying private companies are worthless. The trade is that the wrapper premium is still priced like it has no release valve.

The Mispricing

The market appears to be pricing DXYZ as if it were a direct scarcity asset. On that framing, the wrapper deserves to trade far above filed NAV because public investors cannot easily buy SpaceX, Anthropic, OpenAI, or xAI elsewhere.

That logic overreaches.

The December 31 portfolio was not a pure private-AI basket. It was still heavily cash-like. Post-year-end deployment changed the mix, but spending existing cash into new positions does not mechanically create new net asset value. It changes composition. It does not, by itself, justify a stock price that still implies a roughly 173.4% premium to the latest official NAV.

The second error is structural. Closed-end fund premiums can persist. They do not persist forever when the issuer can actively sell stock above NAV. That is the closing mechanism here. Management already used the Jefferies program once at scale. If the premium stays irrationally wide, selling more stock is economically attractive to the vehicle and accretive to existing NAV.

In plain English, the market is capitalizing private-tech scarcity while underpricing the issuer's ability to manufacture more float into that scarcity.

Price

Market Level Current Reading Source / Timestamp Why It Matters
DXYZ last quoted price $54.60 OpenAI finance snapshot, Friday, May 8, 2026, 7:53 PM EDT Current market anchor for the trade.
Latest official NAV per share $19.97 Destiny Tech100 SEC prospectus supplement filed February 11, 2026; NAV as of December 31, 2025 Latest hard per-share asset-value anchor.
Premium to latest official NAV 173.4% Calculated from $54.60 versus $19.97 Measures the size of the wrapper premium.
Approximate year-end portfolio value $434.0 million Same SEC supplement, as of December 31, 2025 Total disclosed asset base behind the wrapper.
Cash and cash equivalents $205.3 million Same SEC supplement, as of December 31, 2025 Shows how large the year-end cash-like sleeve still was.
Treasury money market fund weight 46.3% of portfolio Same SEC supplement, as of December 31, 2025 The largest single exposure was still cash-like.
Direct SpaceX economic exposure 16.3% of portfolio Same SEC supplement, combining 12.6% and 3.7% SpaceX-linked positions The main scarcity asset is meaningful, but not the whole vehicle.
OpenAI economic exposure 2.1% of portfolio Same SEC supplement, as of December 31, 2025 A headline name with a much smaller disclosed weight than the tape implies.
Post-year-end new portfolio exposure $127.0 million Same SEC supplement, funded with existing cash and cash equivalents as of February 6, 2026 Important mix change, but not automatic value creation.
Remaining ATM capacity Up to $1.0 billion of common stock Same SEC supplement, February 11, 2026 The premium-compression mechanism is live, not theoretical.
Shares sold under Jefferies in Q4 2025 8,121,853 shares for $244.6 million net proceeds Same SEC supplement Proof that management has already used the premium valve.

The tape is not merely rich. It is rich against a filed asset base and rich against a documented issuance mechanism.

Positioning

Direct live short-interest and borrow-cost data were not safely available in the current run, and that missing evidence matters. This note should not pretend otherwise.

What is visible is the positioning in the price action. StockAnalysis showed DXYZ up 21.33% in the latest session, trading roughly 6.84 million shares, and touching a fresh 52-week high of $55.00. That is reflexive tape behavior, not quiet asset-value convergence.

The other market-structure point is what we could not cleanly verify. Nasdaq's option-chain page did not provide a usable live chain in the current run. If options remain thin or unavailable, price discovery is concentrated in the common stock. That can make upside squeezes nastier, but it also means bearish interest cannot cheaply warehouse downside through listed puts.

The issuer's own positioning is clearer than the crowd's. Management already proved willing to sell stock into premium. The market is long scarcity. The vehicle is long the option to monetize that scarcity.

Catalyst

The first catalyst is reflexive and does not need a conference call. Any meaningful new issuance through the Jefferies at-the-market program can compress the premium because it increases float and converts wrapper enthusiasm into balance-sheet capital.

The second catalyst is the next official portfolio and NAV checkpoint. The precise filing date was not reliably verified in the current run, so this note treats the next disclosure window as near-term but not precisely scheduled. What matters is the direction: the next hard mark has to show whether private-value uplift is large enough to justify the current stock price.

The third catalyst is arithmetic fatigue. Even if the private marks do improve, the market still has to justify paying far above filed NAV for a wrapper that can issue more stock. Premiums like this do not need scandal to compress. They only need the marginal buyer to demand less fantasy.

What can delay the thesis is equally clear. SpaceX, Anthropic, or AI-scarcity headlines can keep the premium elevated. A premium short can be right on value and still lose money on path.

Payoff Map

The cleanest expression is short DXYZ common stock only with a confirmed locate and strict sizing discipline. This is a wrapper-premium short, not a fundamental short on late-stage private AI.

If a liquid listed option chain becomes available later, long-dated puts or a bear put spread would likely be cleaner because they cap squeeze risk. In the current run, live option pricing was not reliable enough to treat options as the primary expression.

The wrong expression is a casual long based on brand-name envy. Buying DXYZ here means paying a large wrapper premium while assuming the issuer will not or cannot use the premium to raise more capital.

Price Target and Probability Map

Scenario Probability Target / Level Return / Payoff Time Horizon Conditions Required Evidence Quality
Top Case 25% $28.00 About +48.7% on a short from $54.60 Four to twelve weeks The market starts valuing DXYZ more like a still-premium closed-end vehicle rather than a direct private-company share, and new issuance or a sober NAV update forces premium compression. Medium
Base Case 50% $40.00 About +26.7% on a short from $54.60 Two to ten weeks The premium compresses materially, but investors still pay up for wrapper scarcity and private-AI narrative optionality. Medium
Bottom Case 25% $75.00 About -37.4% on a short from $54.60 Days to eight weeks SpaceX and Anthropic enthusiasm intensifies, borrow stays tight, and the issuer does not quickly absorb demand through new issuance. Low
Invalidation / Stop Condition n/a Sustained trade above $70.00 on fresh positive asset-value evidence Thesis break, not a price target Immediate through the next disclosure window The market receives evidence that the private book has been marked far higher than current public filings imply and the premium remains durable despite that evidence. Medium

Probability-weighted expected value: Using the price map above, the expected stock level is $45.75. From a $54.60 short-entry anchor, that implies roughly +16.2% probability-weighted expected return before borrow cost, commissions, taxes, and gap risk.

Current market price / level: DXYZ was quoted at $54.60 on Friday, May 8, 2026, 7:53 PM EDT in the latest market snapshot used for this run.

Timestamp: Research completed May 10, 2026, 21:27 Asia/Ho_Chi_Minh (UTC+07:00).

Primary instrument: DXYZ common stock on NYSE.

Alternative expressions considered: Long-dated puts or a bear put spread if a liquid live chain becomes verifiable; no trade if borrow is unavailable or punitive.

Confidence: Medium-low.

What Would Prove This Wrong

The thesis fails if the next official valuation and portfolio disclosure show that per-share NAV rose far more than this note expects and that the rise came from real mark-ups rather than from mere cash deployment. The thesis also fails if the stock can hold a much higher level while the issuer either cannot or does not monetize the premium through new issuance.

A pure price squeeze does not intellectually disprove the note, but it can still invalidate the trade. If DXYZ closes sustainably above $70.00 on fresh asset-value evidence, the setup stops being a disciplined premium short and becomes an expensive argument with the tape.

Risk Audit

Strongest counterargument: The December 31, 2025 NAV is stale. Anthropic, xAI, and SpaceX-related marks may have risen enough that the current premium is not nearly as absurd as the old filing makes it look.

Most fragile assumption: That management will eventually use the premium instead of letting scarcity momentum run unchecked.

What the market may already know: The year-end cash-heavy portfolio is already partly obsolete because the fund deployed another $127.0 million by February 6, 2026 and xAI announced its acquisition by SpaceX on February 2, 2026.

What could make the trade lose money even if the thesis is directionally right: Borrow can tighten, a wrapper squeeze can overshoot any reasonable valuation anchor, and the market can stay irrational longer than the next filing cycle.

Liquidity / execution risks: Volume is real, but gap risk is larger than it looks because this is a narrative-driven wrapper and not a normal fundamental short.

Leverage risks: Leverage is a bad fit. The upside for the short can be attractive, but the pain path can be violent if scarcity demand turns into a squeeze.

Information reliability risks: The latest hard NAV is several months old. That is enough to underwrite a disagreement, but not enough to pretend precision about live private marks.

Invalidation trigger: Sustained trade above $70.00 on a fresh official valuation update that materially narrows the gap between price and NAV.

Publish / revise / reject recommendation: Publish as a medium-low confidence wrapper-premium short. The mispricing is clear enough, but path risk and stale official NAV keep this from being a high-conviction hero trade.

Bottom Line

DXYZ is a fund trading like a direct private share. The latest official NAV was $19.97. The stock still trades around $54.60. The same filing that disclosed the NAV also preserved a $1.0 billion at-the-market issuance valve. That is the disagreement. The best expression is short DXYZ common stock, sized small, only with a confirmed locate. It is not a long, and in the current run it is not cleanly an options trade because live option data were not reliable enough to trust.

Sources

Best Trade Strategy

The trade is short DXYZ common stock, not long. If borrow cannot be confirmed at a tolerable cost, there is no clean trade. In the current run, a live options expression was not reliable enough to underwrite as the primary vehicle.